| Gabriella Santos, | |
|
7002 Riverbrook Dr Ste 500, Sugar Land, TX 77479-6589 | |
| (281) 343-7125 | |
| Not Available |
| Full Name | Gabriella Santos |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 7002 Riverbrook Dr Ste 500, Sugar Land, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396216503 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 118615 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gabriella Santos, 12325 Shadow Creek Pkwy Apt 10108, Pearland, TX 77584-7389 Ph: (321) 480-0705 | Gabriella Santos, 7002 Riverbrook Dr Ste 500, Sugar Land, TX 77479-6589 Ph: (281) 343-7125 |
News Archive
Moffitt Cancer Center and Cvergenx announced a new research partnership that aims to revolutionize radiation therapy. The goal of the Future of Radiation Therapy project is to create a framework for using a patient's genetic information to provide a personalized radiation treatment plan.
Adolescents harming themselves with cuts, scratches or burns has gained a lot of attention over the years not just because of the physical damage and internal turmoil, but also because it has been linked to suicide. More recently, a new form of self-harm in youth has emerged and is cause for concern, warns a researcher and bullying expert from Florida Atlantic University.
Warren Kindzierski, University of Alberta researcher in the School of Public Health, says people living in the communities of Fort McMurray, Fort Mckay and Fort Chipewyan should feel confident that the air they are breathing is safe.
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
› Verified 2 days ago
Dr. Annie Francis Uralil, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 14815 Walbrook Dr, Sugar Land, TX 77478 Phone: 281-722-3300 Fax: 281-933-3327 | |
Omair Ahmad, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 6514 Highway 90a Ste 100, Sugar Land, TX 77498 Phone: 281-942-8282 Fax: 346-200-3198 | |
Joseph A Elias, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 16811 Southwest Fwy Ste 200, Sugar Land, TX 77479 Phone: 281-276-8580 Fax: 713-799-9595 | |
Dr. Michael Paul Abdelsayed, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 16902 Southwest Fwy Ste 100, Sugar Land, TX 77479 Phone: 713-527-0120 Fax: 713-527-8131 | |
Mr. Zachary Scott Jacobs, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 17520 W Grand Pkwy S, Sugar Land, TX 77479 Phone: 281-725-5895 Fax: 281-725-5898 | |
Sean M Hayes, PT CSCS Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 20403 University Blvd, Suite 100, Sugar Land, TX 77478 Phone: 281-325-0188 Fax: 281-325-0189 |